Treatment with the anti-epidermal growth factor receptor antibody-drug conjugate becotatug vedotin, compared with chemotherapy, results in significant improvements in objective response rate (ORR) and progression-free survival (PFS) among patients with heavily pretreated and immunotherapy-exposed recurrent or metastatic nasopharyngeal carcinoma (NPC), according to a study.